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Prospective evaluation of the quality of life in a 
cohort of patients with early rheumatoid arthritis
Licia Maria Henrique da Mota1, Ieda Maria Magalhães Laurindo2, Leopoldo Luiz dos Santos Neto3
ABSTRACT
Introduction: Few studies have prospectively assessed the tools used to measure quality of life, both generic and specific, 
in patients with early rheumatoid arthritis (RA). Objective: The objective of this study was to characterize a population 
of patients with early RA (less than 12 months after symptom onset at the time of the diagnosis) prospectively followed 
for the pattern of responses to questionnaires addressing quality of life, the Health Assessment Questionnaire (HAQ) 
and Medical Outcomes Study SF-36 Health Survey (SF-36). Patients and methods: Forty patients with early RA at the 
time of diagnosis, treated with a standard treatment regimen, were prospectively followed for 3 years. Demographic and 
clinical data were recorded, and HAQ and SF-36 questionnaires were applied at baseline and after 3, 6, 12, 18, 24, and 
36 months. Paired Student t test and Wilcoxon test were used for comparisons (significance level of 5%). Results: The 
mean age was 45 years, with a prevalence of the female gender (90%). The average score of the initial HAQ was 1.89, 
with a progressive decline to 0.77 in the third year (P < 0.0001). Most domains of the SF-36 questionnaire presented 
significant improvement during the three years of follow-up, except for general health and vitality. Conclusion: In this 
population of patients with early RA at the time of diagnosis, the results showed significant impact on quality of life at 
the time of diagnosis, as measured by HAQ and SF-36 questionnaires. The early treatment of RA seems to be associated 
with improved health-related quality of life reported by patients.
Keywords: early rheumatoid arthritis, cohort, HAQ, SF-36, quality of life.
INTRODUCTION
Even in its initial stages, rheumatoid arthritis (RA) can cause 
considerable impact on health-related quality of life (HRQoL).1 
HRQoL is a broad concept that can be simplified as the 
impact of health on the functional capacity and well-being of 
an individual perceived on the physical, mental, and social 
domains of life.2
Several tools have been proposed to evaluate the quality of 
life in AR patients, detect health changes and prognosis along 
time, as well as risks and benefits of a specific therapeutic 
intervention,3 including both generic, such as the SF-36 
(Medical Outcomes Study 36-Item Form Health Survey), and 
specific tools, such as the Health Assessment Questionnaire 
(HAQ).
Few studies have prospectively evaluated the tools used 
to measure quality of life, overall in patients with early RA.
The objective of the present study was to characterize a 
population of patients with early RA prospectively followed 
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PATIENTS AND METHODS
A prospective study with an incident cohort was undertaken, in 
which consecutive patients with a diagnosis of early RA,were 
followed regularly for 36 months from the time of diagnosis 
onward, were regularly seen. Patients were evaluated in the 
Early Rheumatoid Arthritis Outpatient Clinic of the University 
Hospital of Brasília, Brazil.
Early RA was defined as articular symptoms compatible 
with the disease (inflammatory pain pattern edema of the joints, 
associated or not with morning stiffness or other manifestations 
suggestive of articular inflammatory disease, according to the 
evaluation of a single observer) lasting more than 6 months 
and less than 12 months, regardless of whether they met 
or not the classification criteria of the American College of 
Rheumatology (ACR).4 During follow-up, the diagnosis of 
RA was confirmed in all patients.
Investigation of rheumatoid factor (RF) was performed 
using the “Quanta LiteTM RF IgA ELISA”, “Quanta LiteTM 
RF IgG ELISA”, and “Quanta LiteTM RF IgM ELISA” assays 
(Inova Diagnostics, CA, USA), according to the protocols of 
the manufacturer. The cutoffs used to consider the test positive, 
i.e., higher than 15 IU/mL (RF IgM and IgA) and 20 (IU/mL 
(RF IgG) were determined. The “Quanta LiteTM CCP IgG 
ELISA”, “Quanta LiteTM CCP3 IgG ELISA”, and “Quanta 
LiteTM CCP 3.1 IgG ELISA” (Inova Diagnostics, CA, USA) 
were used to determine anti-CCP, according to the protocol 
of the manufacturer. Results were expressed in units (U) and 
considered negative when < 20 U, weakly positive 20-39 U, 
moderately positive 40-59 U, and strongly positive ≥ 60 U 
for all assays.
The presence of erosion on conventional X-ray on the first 
appointment was also recorded.
Translated and validated versions of the HAQ and SF-36 
in Portuguese were used to evaluate the impact of early RA 
on quality of life.6
Demographic and clinical data, as well as the results of the 
questionnaires applied in the initial evaluation and at 3, 6, 12, 
18, 24, and 36 months, were recorded.
During follow-up, patients received the standard treatment 
used by our service, including traditional disease-modifying 
drugs (DMARDs) and/or drugs that modify the biological 
response as needed.
The normalcy Kolmogorov-Smirnov test was used and the 
distribution was considered normal if P > 0.05. To detect the 
differences between two means, the Student t test or paired t 
test was used for samples with normal distribution, and the 
non-parametric Wilcoxon or Mann-Whitney test for those 
samples in which the hypothesis of normalcy was rejected. 
Results were considered significant if P < 0.05.
Cohort size calculation was done based on a pilot sample of 
10 patients, considering that a multivariate analysis of variance 
for repeated measurements for interaction among groups 
was the statistical methodology used. Considering a level of 
significance of 5%, a test power of 80%, and the information 
obtained with the pilot sample, a minimum of 40 patients was 
regarded as necessary.
This study was approved by the Ethics on Research 
Committee of the Medical School of Universidade de Brasília 
(Project registration: CEP-FM 028/2007).
RESULTS
Characteristics of the study population
Forty patients with a diagnosis of early RA were evaluated. The 
female gender predominated (36 patients, 90%), with a mean 
age of 45.3 (21 to 71) years. The mean duration of articular 
symptoms at the time of diagnosis was 27.2 weeks (4 to 48), 
but 13 patients (32.5%) had had the symptoms for less than 
12 weeks. The majority of the patients (92%) had not received 
treatment for RA before the initial evaluation.
Patients were not lost for follow-up during the three years 
of the study.
Table 1 summarizes the demographic, clinical, serologic, 
and radiographic characteristics of the study population.
Therapeutic schedules
On the initial evaluation, all 40 patients were taking non-
steroidal anti-inflammatory drugs (NSAIDs) and two of them 
(5%) were on less than 10 mg/day of prednisone (mean time 
of prednisone use of 14.6 ± 2.4 weeks).
After the initial evaluation, 37 patients (92.5%) 
were treated with methotrexate (initial dose of 7.5 mg/
week) with folic acid supplementation (5 mg/week) and 
hydroxychloroquine (400 mg/day), and one individual 
(2.5%) was started on isolated methotrexate (initial dose 
of 7.5 mg/week) with folic acid supplementation (5 mg/
week) because he refused to take hydroxychloroquine. 
Two patients (5%) with pulmonary manifestations received 
cyclophosphamide (0.8 and 1 g/m2) and monthly pulses 
of methylprednisolone (1 g). Two patients with cutaneous 
vasculitis used, in addition to DMARDs, prednisone with 
an initial dose of 40 mg/day.
Figure 1 summarizes the therapeutic schedules used after 
three years.
Quality of life in early RA
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After the three-year follow-up, eight patients (20%) remained 
on the same drugs prescribed initially – hydroxychloroquine 
(mean dose of 400 mg/day) and methotrexate (mean dose of 
20.5 mg/week).
Twenty-three individuals (57.5%) were on a non-
biological DMARD that was different from the one prescribed 
initially. One patient was on methotrexate (15 mg/week), 
hydroxychloroquine (400 mg/day), and leflunomide (20 mg/
day); six others were on methotrexate (mean dose 19.5 mg/
week), hydroxychloroquine (400 mg/day), and sulfasalazine 
(mean dose 1 g/day); nine were on monotherapy with 
leflunomide (20 mg/day); and one patient on leflunomide (20 
mg/day) and cyclosporine (100 mg/day).
Quality of life questionnaires
The difference between the final and initial HAQ scores and 
that of some domains of the SF-36 showed normal distribution, 
except for the emotional and physical aspects, mental health, 
and vitality domains.
Table 2 and Figures 2 and 3 show the baseline scores and 
those obtained after three years of follow-up at the quality of 
life questionnaires, HAQ and SF-36. The scores on HAQ and 
most of the domains for the SF-36 (except for general status and 
vitality domains) showed a significant improvement between 
the baseline evaluation and that performed after three years.
DISCUSSION
Several studies have used the HAQ7 and, therefore, it is possible 
to make comparisons among the results of the present study 
with those of other populations of patients with the diagnosis 
of early RA.
The published studies have demonstrated a wide range of 
variation of the mean HAQ scores in the initial assessment, but 
Table 1
Demographic, clinical, serologic, and radiographic 
characteristics of 40 patients with early RA 
in a prospective follow-up at HUB
Characteristics n (±) ou n (%)

















Duration of symptoms before 
the diagnosis (weeks)
27.22 (± 15.59)




Persistent synovitis in the hands 32 (80%)
Duration of morning 
stiffness (minutes)
155.5 (± 117.97)
Number of painful joints 20.07 (± 6.74)
Number of joints with edema 14.15 (± 7.64)
Rheumatoid nodules 5 (12.5%)



























DAS28 6.86 (± 1.07)
Radiographic erosion 21 (52.5%)
RF (RF IgA, RF IgG and/or RF IgM) 21(52.5%)
Anti-CCP (CCP2, CCP3 
and/or CCP3.1)
21(52.5%)
Results presented as mean (± standard deviation) or n (%). 
RF = rheumatoid factor; DAS = Disease activity index.
DMARD = Disease-modifying anti-rheumatic drugs.
Figure 1
Treatment schedules used by 40 patients with a diagnosis of 
early RA , at baseline and after three years of follow-up.
Methotrexate + hydroxychloroquine (n = 8)
Methotrexate + hydroxychloroquine  
+ leflunomide (n = 1)
Methotrexate + hydroxychloroquine  
+ sulfassalazina (n = 3)
Methotrexate + sulfassalazina (n = 3)
Leflunomide (n = 9)
Leflunomide + cyclosporine (n = 1)
Infliximab + methotrexate (n = 4)
Etanercept + methotrexate (n = 2)
Adalimumab + methotrexate (n = 1)
Rituximab + methotrexate (n = 2)
Methotrexate + leflunomide (n = 6)
Initial therapy
n = 8 (20%)
Change in 
DEMARD
n = 23 (57.5%)
Biological 
therapy
n = 9 (22.5%)
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the mean score in the majority of them is around 1 (0.8 to 1.3),8-11
which was lower than the one observed in our population, 
whose mean HAQ scores at the initial evaluation was 1.9, 
decreasing to 0.8 after three years of follow-up.
Although most studies have shown an improvement in 
HAQ scores throughout the first few years after the diagnosis 
of RA, a wide variation can be observed regarding the rate 
of change in HAQ. After two years of follow-up, 10% of 
147 patients in the study by van der Heijde et al.,12 and 29%, 
in the study by Wiles et al.,9 still had a HAQ score greater 
than 1. Combe et al.11 reported that 27% of 191 patients had 
HAQ scores > 1 after three years of follow-up, and 22% still 
maintained this mean score after five years of treatment. The 
study by Young et al.8 showed 34% and 38% for the same 
periods of time (three and five years). Possible explanations 
for variations in the evolution of HAQ scores include different 
study designs and the influence of other parameters, such as 
the effects of treatment and socioeconomic status.13
Six large studies in patients with early RA in the United 
Kingdom – NOAR14 and ERAS15 – Sweden, France, and 
Holland,16-19 showed that the behavior of the HAQ presents a 
“J curve” pattern, demonstrated by an initial fall in HAQ scores 
followed by a gradual increase along the years. In those studies, 
the mean initial HAQ score was 0.92 (ranging from 0.63 to 
1.3). After three years, the mean score decreased to 0.74, but 
a subsequent increase of up to 0.83 occurred in the fifth year.
A possible explanation for this “J curve” pattern is that 
RA patients experience considerable difficulty before starting 
the treatment. Initially, the use of NSAIDs and DMARDs 
improve the synovitis and the incapacity associated with it. 
However, functional limitation increases slowly and gradually 
with the progression of the articular damage and other disease 
Table 2
HAQ and SF-36 scores of 40 patients with a diagnosis of early RA in prospective 
follow-up at HUB – baseline assessment and after three years
Questionnaires
Mean Evaluation (standard deviation)
T PBaseline Three years
HAQ 1.89(0.78) 0.77(0.64) 7.49 < 0.0001
SF-36 (Domains)
Social aspects 41.87(34.27) 77.24(26.42) -5.77 < 0.0001
Pain 23.00(19.77) 57.51(23.14) -7.08 < 0.0001
General status 57.35(25.86) 66.33(23.72) -1.77 0.08
Functional capacity 23.50(25.32) 56.28(29.22) -5.32 < 0.0001
Questionnaires
Evaluation Median (interquartile amplitude)
Wilcoxon test PBaseline Three years
SF-36 (Domains)
Mental health 52.00(20.00) 56.00(12.00) 133.00 0.03
Emotional aspects 0(0) 66.67(100.00) 139.50 < 0.0001
Vitality 50.00(15.50) 50.00(20.00) 14.00 0.08
Physical aspects 0(0) 25.00(100.00) 146.50 < 0.0001
HUB = Hospital Universitário de Brasília; RA = rheumatoid arthritis; HAC = Health Assessment Questionnaire; SF-36 = Medical Outcomes Study 36-Item Form Health Survey.
Figure 2
Mean HAQ scores of 40 patients with a diagnosis of early RA 
in prospective follow-up at HUB for three years.
HUB = Hospital Universitário de Brasília; RA = rheumatoid arthritis;  
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Figure 3
Scores (means-paired t test, and medians-Wilcoxon) of the domains of the SF-36 of 40 patients with a diagnosis of early RA in 
the prospective follow-up at HUB for three years.
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manifestations.20 In the present study, the improvement in 
HAQ scores was fast (large decrease in the score in the first 
six months of treatment), but progressive worsening (increase 
in HAQ scores) between the sixth and 30th month of treatment 
occurred. From the 30th month until the end of the 36th month a 
progressive improvement was observed once again, reaching 
a mean level that was significantly lower than the initial level.
As for the SF-36 questionnaire, the reduced levels of the 
scores of the domains in the initial evaluation demonstrated 
a great impact on the health-related quality of life in our 
population of patients with early RA. The domains “physical 
limitation” and “emotional limitation” showed very low scores, 
demonstrating that, in our study population, those were the 
most affected aspects of quality of life at the initial evaluation. 
The “mental health” and “vitality” domains were the least 
affected at the time of the diagnosis.
West and Jonsson reported the SF-36 score in a group of 40 
patients with initial RA followed for two years. At the initial 
evaluation, patients had lower scores (worse) for all eight 
domains of the SF-36 when compared to the control group. 
After two years, patients reported improvement in several 
domains, including pain and physical function.21
Comparison with other cohorts is less feasible when the 
SF-36 questionnaire is used, when compare to HAQ, since very 
few prospective studies on patients with early RA using the 
SF-36 can be found in the literature. Moreover, as the SF-36 
is a generic tool, not specific for RA, therefore influenced by 
other conditions, such as age, gender, socioeconomic status, 
presence of comorbidities, as well as symptoms of depression 
and fibromyalgia,22 it becomes difficult to compare scores 
among different populations.
Uhlig et al.23 and Talamo et al.24 published the results of the 
analysis of the HRQol in 1,052 patients of the Oslo RA Registry 
and 137 English patients, respectively. Both reported better 
performance than our population in six domains of the SF-36, 
except for “general status” and “vitality”, which had higher 
scores in the population of the present study. However, neither 
the Norwegian nor the English studies evaluated patients with 
initial RA, but rather individuals with established RA (13.8 
and 11 years of mean disease evolution, respectively) treated 
with DMARDs and biological drugs, which makes it difficult 
to compare them with the initial data of our cohort.
In the present study, all evaluated domains, except 
for general health status and vitality, showed significant 
improvement throughout three years of follow-up. The final 
scores obtained in our cohort were similar to that of the study 
by Wiles et al.25 regarding the fifth year of follow-up of 303 
patients with a diagnosis of initial RA of the NOAR cohort.
A study similar to the present one, which evaluated the 
profile of the evolution of SF-36 domains along time, cannot 
be found in the literature. In the present study, the different 
pattern of the domains along the 36 months of follow-up could 
reflect several impacts of the disease and its treatment on the 
characteristics evaluated or be attributed to the subjectivity of 
the responses to the questionnaire, which can be influenced 
by other aspects.
The population followed in our study showed a greater 
impact of RA on quality of life, according to the evaluation 
obtained by the HAQ and SF-36, at the time of the diagnosis, 
when compared to other studies. On the other hand, a 
considerable improvement in disability was observed during 
the first months of treatment, which persisted until the end of 
the third year. The early treatment of RA, in our cohort, seemed 
to be associated with improvement in health-related quality of 
life reported by the patients.
CONCLUSIONS
The population evaluated in the present study presented a great 
impact of RA on their quality of life, according to the HAQ 
and SF-36, at the time of the diagnosis, which was greater than 
that presented by other studies.
In patients with early RA receiving standard treatment 
for the disease, a significant improvement in quality of life, 
evaluated by the HAQ and in the majority of the physical health 
components of the SF-36, except for general health status and 
vitality, was observed. The early treatment of RA seems to be 
associated with improvement in health-related quality of life 
reported by the patients.
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